Austin, Texas, United States, March 23rd, 2026, FinanceWire
- Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.
- The UK Medicines and Healthcare Products Regulatory Agency granted Promising Innovative Medicine designation to Soligenix’s SGX945 (dusquetide) for the treatment of Behçet’s disease.
- The recent designation in the United Kingdom builds on other regulatory recognitions previously granted to dusquetide.
Regulatory recognition from international health authorities can significantly shape the trajectory of emerging therapies worldwide, particularly in rare disease development where clinical pathways are often complex and resource intensive. Soligenix (NASDAQ:SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and unmet medical needs, recently received such recognition as its investigational therapy SGX945 was granted Promising Innovative Medicine (“PIM”) designation by the United Kingdom’s (“UK’s”) Medicines and Healthcare products Regulatory Agency (“MHRA”).
Designations granted by leading regulatory agencies play a critical role in advancing drug-development programs. These recognitions often signal that a therapy shows potential to address serious conditions where few treatment options exist. According to the UK MHRA, the PIM designation is awarded to…
Read More>>
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
Contact
IBN
www.InvestorBrandNetwork.com
Editor@InvestorBrandNetwork.com
If you want to submit your press release through TipRanks NewsWire, please go to the following link.